525 related articles for article (PubMed ID: 18563688)
1. [Chemotherapy of malignant pleural mesothelioma: have we made any progress?].
Reck M; Heigener DF; Gatzemeier U
Zentralbl Chir; 2008 Jun; 133(3):238-42. PubMed ID: 18563688
[TBL] [Abstract][Full Text] [Related]
2. Pemetrexed and cisplatin for malignant pleural mesothelioma: a new standard of care?
Rusch VW
J Clin Oncol; 2003 Jul; 21(14):2629-30. PubMed ID: 12860935
[No Abstract] [Full Text] [Related]
3. Pemetrexed-cisplatin combination in mesothelioma.
Reck M; Gatzemeier U
Expert Rev Anticancer Ther; 2005 Apr; 5(2):231-7. PubMed ID: 15877521
[TBL] [Abstract][Full Text] [Related]
4. Raltitrexed plus cisplatin is cost-effective compared with pemetrexed plus cisplatin in patients with malignant pleural mesothelioma.
Woods B; Paracha N; Scott DA; Thatcher N
Lung Cancer; 2012 Feb; 75(2):261-7. PubMed ID: 21937141
[TBL] [Abstract][Full Text] [Related]
5. [First-line treatment with pemetrexed in association with cisplatin in patients with non-operable malignant pleural mesothelioma].
Burgin M; Gairard-Dory A-; Mennecier B; Molard A; Beretz L; Quoix A-
Rev Pneumol Clin; 2009 Apr; 65(2):75-83. PubMed ID: 19375046
[TBL] [Abstract][Full Text] [Related]
6. Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access program.
Obasaju CK; Ye Z; Wozniak AJ; Belani CP; Keohan ML; Ross HJ; Polikoff JA; Mintzer DM; Monberg MJ; Jänne PA;
Lung Cancer; 2007 Feb; 55(2):187-94. PubMed ID: 17092602
[TBL] [Abstract][Full Text] [Related]
7. Future developments in the management of malignant pleural mesothelioma.
Zucali PA; De Vincenzo F; Simonelli M; Santoro A
Expert Rev Anticancer Ther; 2009 Apr; 9(4):453-67. PubMed ID: 19374599
[TBL] [Abstract][Full Text] [Related]
8. Second-line treatment for malignant pleural mesothelioma.
Ceresoli GL; Zucali PA; Gianoncelli L; Lorenzi E; Santoro A
Cancer Treat Rev; 2010 Feb; 36(1):24-32. PubMed ID: 19879055
[TBL] [Abstract][Full Text] [Related]
9. The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline.
Ellis P; Davies AM; Evans WK; Haynes AE; Lloyd NS;
J Thorac Oncol; 2006 Jul; 1(6):591-601. PubMed ID: 17409924
[TBL] [Abstract][Full Text] [Related]
10. Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial.
Guadagni S; Clementi M; Valenti M; Fiorentini G; Cantore M; Kanavos E; Amicucci G
In Vivo; 2006; 20(6A):715-8. PubMed ID: 17203752
[TBL] [Abstract][Full Text] [Related]
11. Adapting the Lung Cancer Symptom Scale (LCSS) to mesothelioma: using the LCSS-Meso conceptual model for validation.
Hollen PJ; Gralla RJ; Liepa AM; Symanowski JT; Rusthoven JJ
Cancer; 2004 Aug; 101(3):587-95. PubMed ID: 15274072
[TBL] [Abstract][Full Text] [Related]
12. Pemetrexed in the treatment of malignant mesothelioma: results from an expanded access program in Germany.
Reck M; Stahel RA; von Pawel J; Karthaus M; Korfee S; Serke M; Schuette WH; Eschbach C; Fink TH; Leschinger MI; Manegold C
Respir Med; 2010 Jan; 104(1):142-8. PubMed ID: 19818589
[TBL] [Abstract][Full Text] [Related]
13. [Malignant mesothelioma of the pleura: place of surgery].
Giudicelli R; Regnard JF; Astoul P; Ruffie P
Rev Mal Respir; 2006 Sep; 23(4 Pt 2):10S106-10S109. PubMed ID: 17127980
[No Abstract] [Full Text] [Related]
14. Pemetrexed in malignant pleural mesothelioma.
Hazarika M; White RM; Booth BP; Wang YC; Ham DY; Liang CY; Rahman A; Gobburu JV; Li N; Sridhara R; Morse DE; Lostritto R; Garvey P; Johnson JR; Pazdur R
Clin Cancer Res; 2005 Feb; 11(3):982-92. PubMed ID: 15709163
[TBL] [Abstract][Full Text] [Related]
15. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
van Meerbeeck JP; Gaafar R; Manegold C; Van Klaveren RJ; Van Marck EA; Vincent M; Legrand C; Bottomley A; Debruyne C; Giaccone G; ;
J Clin Oncol; 2005 Oct; 23(28):6881-9. PubMed ID: 16192580
[TBL] [Abstract][Full Text] [Related]
16. Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.
Zucali PA; Simonelli M; Michetti G; Tiseo M; Ceresoli GL; Collovà E; Follador A; Lo Dico M; Moretti A; De Vincenzo F; Lorenzi E; Perrino M; Giordano L; Farina G; Santoro A; Garassino M
Lung Cancer; 2012 Mar; 75(3):360-7. PubMed ID: 21937142
[TBL] [Abstract][Full Text] [Related]
17. [Prognosis related clinical and molecular factors in malignant pleural mesothelioma].
Wang YY; Zhang H; Bai H; Wang SH; Wu MN; An TT; Zhao J; Zhuo ML; Duan JC; Wang ZJ; Wang J
Zhonghua Jie He He Hu Xi Za Zhi; 2013 Mar; 36(3):162-8. PubMed ID: 23856136
[TBL] [Abstract][Full Text] [Related]
18. [A case of malignant pleural mesothelioma that responded to cisplatin plus pemetrexed rechallenge].
Shukuya T; Takahashi T; Nakamura Y; Yamamoto N
Gan To Kagaku Ryoho; 2010 Mar; 37(3):487-90. PubMed ID: 20332689
[TBL] [Abstract][Full Text] [Related]
19. Carboplatin and pemetrexed in the management of malignant pleural mesothelioma: a realistic treatment option?
Li L; Razak AR; Hughes A
Lung Cancer; 2009 May; 64(2):207-10. PubMed ID: 18926592
[TBL] [Abstract][Full Text] [Related]
20. Nursing considerations for administering pemetrexed (Alimta) in combination with cisplatin for malignant pleural mesothelioma.
Orbaugh KK
Clin J Oncol Nurs; 2004 Jun; 8(3):242-7. PubMed ID: 15208818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]